Avoro Capital Advisors’s Whitehawk Therapeutics WHWK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.83M Hold
2,849,402
0.1% 30
2025
Q4
$6.9M Hold
2,849,402
0.07% 33
2025
Q3
$5.41M Hold
2,849,402
0.07% 29
2025
Q2
$5.33M Hold
2,849,402
0.09% 30
2025
Q1
$5.07M Hold
2,849,402
0.08% 33
2024
Q4
$8.99M Hold
2,849,402
0.13% 39
2024
Q3
$5.87M Hold
2,849,402
0.09% 34
2024
Q2
$4.16M Hold
2,849,402
0.06% 38
2024
Q1
$6.67M Hold
2,849,402
0.08% 45
2023
Q4
$5.76M Hold
2,849,402
0.08% 42
2023
Q3
$13.8M Hold
2,849,402
0.22% 36
2023
Q2
$19.5M Hold
2,849,402
0.26% 33
2023
Q1
$20.6M Hold
2,849,402
0.31% 30
2022
Q4
$36.6M Hold
2,849,402
0.55% 27
2022
Q3
$40.3M Buy
2,849,402
+1,020,000
+56% +$13.4M 0.74% 22
2022
Q2
$22.5M Hold
1,829,402
0.45% 29
2022
Q1
$31M Hold
1,829,402
0.57% 27
2021
Q4
$44.2M Hold
1,829,402
0.75% 21
2021
Q3
$53.7M Buy
1,829,402
+1,529,402
+510% +$46.6M 0.84% 23
2021
Q2
$7.61M Buy
+300,000
New +$6.85M 0.13% 44

Other funds holding WHWK

Avoro Capital Advisors's WHWK Position: Q1 2026 in Review

Avoro Capital Advisors held its Whitehawk Therapeutics (WHWK) position steady in Q1 2026 at 2,849,402 shares worth $9.83M. The position accounts for 0.1% of the portfolio, ranked #30.

Avoro Capital Advisors first reported a position in WHWK in Q2 2021 and has held it in 20 quarters since. The position peaked at $53.7M in Q3 2021. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Avoro Capital Advisors held 2,849,402 shares of Whitehawk Therapeutics worth $9.83M as of Q1 2026.
  • Avoro Capital Advisors left its Whitehawk Therapeutics share count unchanged in Q1 2026.
  • Whitehawk Therapeutics made up 0.1% of Avoro Capital Advisors's portfolio in Q1 2026, its #30 holding.
  • Avoro Capital Advisors first reported a position in Whitehawk Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Avoro Capital Advisors's Whitehawk Therapeutics position peaked at $53.7M in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Avoro Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.